Epstein-Barr, Antibodies (IgG) anti-VCA. Screening.

Clinical information

Diagnostic Utility:

This is the qualitative detection of IgG antibodies against the viral capsid antigen (VCA) of the Epstein-Barr virus (EBV) and its determination is useful in:

• Diagnosis of infectious mononucleosis (IM).
• Determining the stage of EBV infection.

Method:

Chemiluminescence microparticle immunoassay (CMIA).

Reference Values

Possible results are: Reactive and Non-Reactive.

Diagnostic Algorithm:

Not applicable.

Turnaround Time:

Maximum 2 working days.

Specimen information

Sample: Serum and/or plasma
Tube: Aliquots of 1-5 mL, plasma tubes with EDTA, citrate, or heparin as anticoagulant and/or serum tubes with or without gel separator.
Minimum essential volume: 1 ml
Stability:

• At room temperature: ≤ 3 days
• At 2-8 ºC refrigeration: ≤14 days
• Sample frozen at or below -20ºC: 10 years

Transport instructions: Preferably at room temperature if it is whole blood tubes, and refrigerated if it is serum and/or plasma aliquots.

Reason for rejection: Highly hemolyzed sample

Administrative information

BST Code: 2108
Test Description: Epstein-Barr, Antibodies (IgG) anti-VCA. Screening.
Synonyms: EBV VCA IgG
Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates here.

Profiles:

Test 2108 Epstein-Barr, Antibodies (IgG) anti-VCA. Screening can be requested alone or with the profile:

References

• Inserts kits de EBV VCA IgG Architect, Abbott.

Quality

BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.